PrefixTitleTypeCategory
C25Characterizing the effect of the COVID-19 pandemic on PEPFAR-supported voluntary medical male circumcision services, 2020E-posterMale circumcision
C25Changes in the quality of voluntary medical male circumcision services in selected districts of the Mpumalanga, Eastern Cape, Free State and North West Provinces of South AfricaE-posterMale circumcision
C25HIV Prevention in COVID-19 lockdown: The impact of suspending VMMC in SA and the subsequent effects on HIV transmission dynamicsE-posterMale circumcision
C25Demand creation and voluntary medical male circumcision during COVID-19 pandemicE-posterMale circumcision
C25Association between medical male circumcision and HIV risk compensation among heterosexual men: a systematic review and meta-analysisE-posterMale circumcision
C25Experience with ShangRing circumcision in Malawi voluntary medical male circumcision programE-posterMale circumcision
B39Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population)On-demand oral abstract sessionLong-acting agents and other drug delivery systems
B39Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE)Oral abstract session with live Q&ALong-acting agents and other drug delivery systems
D68Pathways from childhood abuse to adulthood mental health challenges: applying theories of accumulating health risks with a longitudinal cohort of women living with HIV in CanadaE-posterLiving with HIV and co-infections and/or co-morbidities
D68Factors associated with impaired self-reported quality of life in males and females living with HIV in south-western France (QuAliV - ANRS CO3 Aquitaine cohort)E-posterLiving with HIV and co-infections and/or co-morbidities
431 - 440 of 870 items